Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. More Details
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Cannara Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LOVE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: LOVE's weekly volatility (12%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: LOVE underperformed the Canadian Pharmaceuticals industry which returned 47.2% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 1.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cannara Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StHave Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
2 months ago | Simply Wall StCannara Biotech (CSE:LOVE) Is Carrying A Fair Bit Of Debt
3 months ago | Simply Wall StCannara Biotech (CSE:LOVE) Share Prices Have Dropped 44% In The Last Year
Is Cannara Biotech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LOVE is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LOVE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LOVE's PB Ratio (2.6x) is in line with the CA Pharmaceuticals industry average.
How is Cannara Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of LOVE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Cannara Biotech competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Cannara Biotech performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LOVE is currently unprofitable.
Growing Profit Margin: LOVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LOVE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LOVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LOVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).
Return on Equity
High ROE: LOVE has a negative Return on Equity (-34.13%), as it is currently unprofitable.
How is Cannara Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: LOVE's short term assets (CA$10.5M) exceed its short term liabilities (CA$3.5M).
Long Term Liabilities: LOVE's short term assets (CA$10.5M) do not cover its long term liabilities (CA$13.0M).
Debt to Equity History and Analysis
Debt Level: LOVE's debt to equity ratio (32%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LOVE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LOVE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LOVE has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.8% each year.
What is Cannara Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LOVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LOVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LOVE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Zohar Krivorot (43 yo)
Mr. Zohar Krivorot is Founder, President, Chief Executive Officer and Director at Cannara Biotech Inc. since December 31, 2018 and also serves as its Chairman. A successful entrepreneur, Mr. Krivorot has f...
CEO Compensation Analysis
Compensation vs Market: Zohar's total compensation ($USD72.48K) is below average for companies of similar size in the Canadian market ($USD153.12K).
Compensation vs Earnings: Zohar's compensation has been consistent with company performance over the past year.
|Founder||no data||CA$92.31k||no data|
|Executive Officer||0.17yr||CA$300.00k||0% |
|Interim Chief Financial Officer||0.17yr||no data||0.098% |
|Vice President of Finance & Accounting||1yr||no data||no data|
|VP Compliance & GM||no data||no data||no data|
|Senior Vice President of Marketing & Sales||no data||no data||no data|
|Chief of Staff||no data||no data||no data|
|Vice President of Business Development||no data||CA$193.63k||no data|
|Executive Officer||no data||CA$300.00k||no data|
Experienced Management: LOVE's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.
|Founder||no data||CA$92.31k||no data|
|Independent Director||1.75yrs||CA$18.50k||0.30% |
|Independent Director||0.17yr||no data||no data|
|Independent Director||2.08yrs||CA$19.00k||no data|
|Independent Director||0.67yr||CA$4.00k||no data|
Experienced Board: LOVE's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.
Cannara Biotech Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cannara Biotech Inc.
- Ticker: LOVE
- Exchange: CNSX
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$99.608m
- Shares outstanding: 737.84m
- Website: https://cannara.ca
Number of Employees
- Cannara Biotech Inc.
- 333 Decarie boulevard
- Suite 200
- H4N 3M9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LOVE||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Jan 2019|
|LOVF.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jan 2019|
|8CB||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 2019|
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. It also offers hemp based CBD products thr...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/17 00:19|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.